EndoCeutics Inc.
Quick facts
Phase 3 pipeline
- DHEA (0.25%) · Women's Health / Gynecology
DHEA (dehydroepiandrosterone) is a prohormone that is converted to estrogen and testosterone in peripheral tissues, restoring hormone levels in postmenopausal women. - DHEA (0.5%) · Gynecology; Menopause
DHEA (dehydroepiandrosterone) is a prohormone that is converted to testosterone and estrogen in peripheral tissues, restoring hormone levels in postmenopausal women. - DHEA (1.0%) · Endocrinology / Women's Health
DHEA is a steroid hormone precursor that acts as a prohormone, being converted in peripheral tissues to testosterone and estrogen to restore hormonal balance. - DHEA and Acolbifene · Women's Health / Endocrinology
DHEA and acolbifene work together as a selective estrogen receptor modulator (SERM) combination to provide estrogen-like benefits in bone and vaginal tissue while minimizing systemic estrogen exposure. - Prasterone (DHEA) · Women's Health / Gynecology
Prasterone (DHEA) is a steroid hormone precursor that acts as a substrate for the synthesis of estrogen and androgen, restoring hormonal balance in postmenopausal women.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about EndoCeutics Inc.
What is EndoCeutics Inc.'s pipeline?
EndoCeutics Inc. has 5 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include DHEA (0.25%), DHEA (0.5%), DHEA (1.0%), DHEA and Acolbifene.
Related
- Sector hub: All tracked pharma companies